Hummingbird Bioscience

Hummingbird Bioscience is a clinical-stage precision biotherapeutics company that discovers and develops antibody-based medicines, including antibody-drug conjugates (ADCs), for cancer and autoimmune disease. The company combines systems biology, structural and computational biology, AI/machine learning and data science to characterize disease targets, identify optimal epitopes, and engineer antibodies against targets it describes as hard to drug. Its stated process spans disease and target biology, lead discovery via its Rational Antibody Discovery (RAD) platform, translational science using human tissue studies, omics and disease models, and clinical development in biomarker-defined patient populations.

The pipeline has centered on HMBD-001, an anti-HER3 monoclonal antibody targeting an epitope that blocks HER3 dimerization and activation, developed for NRG1-fusion and HER3-driven tumors; HMBD-002, a first-in-class anti-VISTA neutralizing antibody for advanced solid tumors; HMBD-009, a BCMA-TACI dual-specific T cell engager; HMBD-802, a first-in-class dual-payload anti-HER2 ADC; and HMBD-501, which entered a Phase I trial in advanced HER3-expressing solid malignancies. HMBD-001 has been evaluated in a Phase I/IIa trial in the UK (NCT05057013) sponsored and managed by Cancer Research UK's Centre for Drug Development, with additional Phase Ib trials initiated in Australia.